MEK Inhibition Aids in Serous Ovarian Cancer

被引：0
|
作者：
不详
机构：
来源：
CANCER DISCOVERY | 2012年 / 2卷 / 05期
关键词：
D O I：
10.1158/2159-8290.CD-NB2012-029
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
In a phase II trial of the experimental MEK inhibitor selumetinib (AZD6244), women who had failed 3 or more rounds of chemotherapy had 81% disease control and a median progression-free survival of 11.3 months.
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Combination immune checkpoint blockade and MEK inhibition in a platinum-resistant ovarian cancer model
    Hartnett, E. G.
    Edwards, R. P.
    Vlad, A.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 53 - 54
  • [42] Serous retinopathy associated with MEK inhibition (binimetinib) for metastatic cutaneous and uveal melanoma
    Boon, Camiel J. F.
    van Dijk, Elon H. C.
    van Herpen, Carla M. L.
    Marinkovic, Marina
    Amundson, Drake
    Luyten, Gregorius P. M.
    Jager, Martine J.
    Kapiteijn, Ellen H. W.
    Keunen, Jan E. E.
    Adamus, Grazyna
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2015, 56 (07)
  • [43] Proposing a new chemotherapeutic drug combination for effective inhibition of serous ovarian and endometrial cancer cells
    Gogoi, R. P.
    Dasari, V.
    MOLECULAR BIOLOGY OF THE CELL, 2018, 29 (26) : 247 - 248
  • [44] mTOR complex inhibition as a novel therapeutic strategy in high grade papillary serous ovarian cancer
    Musa, F.
    Alard, A.
    Blank, S.
    Pothuri, B.
    Curtin, J.
    Schneider, R.
    GYNECOLOGIC ONCOLOGY, 2014, 134 (02) : 434 - 435
  • [45] Lithium Chloride and Inhibition of Glycogen Synthase Kinase 3β as a Potential Therapy for Serous Ovarian Cancer
    Novetsky, Akiva P.
    Thompson, Dominic M.
    Zighelboim, Israel
    Thaker, Premal H.
    Powell, Matthew A.
    Mutch, David G.
    Goodfellow, Paul J.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (02) : 361 - 366
  • [46] Therapeutic targeting of the estrogen receptor in ovarian carcinoma by MEK inhibition
    Hou, June Y.
    Goldberg, Gary L.
    Rodriguez-Larocca, Alicia
    Horwitz, Susan B.
    McDaid, Hayley M.
    CANCER RESEARCH, 2010, 70
  • [47] CDK4/6 and MEK inhibitor combination in low-grade serous ovarian cancer cell lines.
    Hoenisch, Joshua
    Kim, Hannah
    Dawson, Amy
    Lam, Nicole
    Cheasley, Dane A.
    Gorringe, Kylie
    Campbell, Ian
    Huntsman, David G.
    DiMattia, Gabriel
    Kobel, Martin
    Fernandez, Marta Llaurado
    Carey, Mark S.
    CLINICAL CANCER RESEARCH, 2020, 26 (13) : 91 - 91
  • [48] Molecular classification of serous ovarian cancer subtypes
    Quackenbush, John
    Fan, Jian-Bing
    Hirsch, Michelle
    Mar, Jessica
    Howe, Eleanor
    Holton, Kristina
    Rubio, Renee
    April, Craig
    Chen, Jing
    Wickham-Garcia, Eliza
    Liu, Joyce
    Culhane, Aedin
    Drapkin, Ronny
    Matulonis, Ursula
    CANCER RESEARCH, 2009, 69
  • [49] Personalized Managing Of The Patients With Serous Ovarian Cancer
    Rybin, Andriy
    Dubinina, Vladlena
    Kuznetsova, Olga
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 35 - 35
  • [50] Autoantibody biomarkers for the detection of serous ovarian cancer
    Katchman, Benjamin A.
    Chowell, Diego
    Wallstrom, Garrick
    Vitonis, Allison F.
    LaBaer, Joshua
    Cramer, Daniel W.
    Anderson, Karen S.
    GYNECOLOGIC ONCOLOGY, 2017, 146 (01) : 129 - 136
12345